Importantly, both pharmaceutical inhibition and genetic silencing of Runx1 effectively blocked MMT in LLC tumors in vivo and TGF‐β1‐stimulated BMDMs in vitro, clearly demonstrating the therapeutic potential of targeting macrophage specific TGF‐β/Smad3/Runx1 signaling to suppress MMT driven tumor growth. The gene discussed is RUNX1; the disease is neoplasm.